Rapid Communication
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 14, 2006; 12(2): 322-326
Published online Jan 14, 2006. doi: 10.3748/wjg.v12.i2.322
Figure 2
Figure 2 Significant decrease of activated and quiescent HSCs by 48-wk losartan treatment in a patient with NASH (double immunostaining with anti-p75 and α-SMA antibodies, × 200).